Evidence map›Paper›PMID 31650354›Full record

Trial reportInternational ophthalmology2020

Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects.

Gonzalo Carracedo-Rodríguez, Alejandro Martínez-Águila, Candela Rodriguez-Pomar, Julia Bodas-Romero, Juan Sanchez-Naves, Jesús Pintor

Open access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gonzalo Carracedo-RodríguezOcupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain. jgcarrac@ucm.es.ORCID http://orcid.org/0000-0003-0054-1731
Alejandro Martínez-ÁguilaAvizor S.A., Madrid, Spain.
Candela Rodriguez-PomarAvizor S.A., Madrid, Spain.
Julia Bodas-RomeroOcupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain.
Juan Sanchez-NavesOcupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain.
Jesús PintorOcupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain.
American Optometric Association · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects. PATIENTS AND

methodsA short-term prospective study was designed. Sixty-seven normotensive subjects were recruited. Patients were divided into two groups. The daily group (DG) (n = 18) was instructed to take the supplement between 22:00 and 23:00 (before sleeping) for 3 consecutive days. IOP was measured from 10.00 to 11.00 am the day before treatment and during the 3 days of experiment. The acute group (AG) (n = 49) was instructed to take the supplement after the second measure (11.00) of the second day. IOP was measured 1 h and just before the intake of the supplement and 1 and 2 h after. All measurements in this group were taken 1 day before without any supplement (control) and the day of experiment.

resultsThe DG group showed a significant decrease in IOP after supplement intake in all days of experiment, from 14.9 ± 3.4 mm Hg to 13.8 ± 2.9 mm Hg after 3 days of experiment (p value < 0.001). For AG, IOP did not change during the control day; however, a reduction of 1 mm Hg was found 2 and 3 h after supplement intake, from 15.7 ± 2.5 mm Hg to 14.7 ± 2.5 mm Hg and 15.1 ± 2.7 mm Hg, respectively, being statistically significant (p value < 0.001).

conclusionThe supplement based on melatonin was able to reduce the IOP in normotensive subjects after 2 h of intake. Moreover, the daily intake showed a reduction in IOP during the 3 days of experiment.

Indexed as

AdultAntioxidantsFemaleFollow-Up StudiesHealthy VolunteersHumansIntraocular PressureMaleMelatoninMiddle AgedNutritional SupportOcular HypertensionProspective StudiesTonometry, OcularYoung AdultAntioxidantsMelatoninCoadjuvant treatmentsIntraocular pressureMelatoninSupplements

Identifiers

PMID31650354
OpenAlexW2982266966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.